Adjuvanted trivalent influenza vaccine (aTIV) and trivalent high dose influenza vaccine (TIV-HD) have shown different clinical benefits, so researchers assessed the annualized mean all-cause and influenza-related total health care costs associated with aTIV versus TIV-HD among patients aged 65 years and older during the 2017-2018 flu season. They found that influenza-related health care costs were comparable for aTIV and TIV-HD. The results of the study were presented during AMCP eLearning Days in a poster presentation titled “Economic Assessment of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine Among the U.S. Elderly: A Comprehensive Real-World Evidence Evaluation of Direct Healthcare Costs for the 2017-2018 Influenza Season.”
This retrospective cohort analysis of older adults was conducted using professional fee, prescription claims, and hospital charge master data in the United States. Researchers assessed age, gender, payer type, region, Charlson Comorbidity Index, location of vaccine receipt, comorbidities, indicators of frail health status, and pre-index hospitalization rates.
Treatment selection bias was adjusted through 1:1 propensity score matching (PSM). Costs included influenza-related hospitalizations, emergency room (ER) visits, and physician office visits, as well as outpatient pharmacy costs.
During the 2017-2018 flu season, the PSM sample included 234,313 patients who received aTIV and 234,313 who received TIV-HD. After generalized estimating equation adjustment, predicted mean annualized all-cause costs per patient were statistically similar: aTIV, $9,999; TIV-HD, $10,022. Influenza-related costs were also similar ($28.21 vs. $31.77, respectively).
Both aTIV and TIV-HD were comparable in terms of predicted mean annualized costs for influenza-related hospitalizations ($27.59 vs. $26.29) and influenza-related ER visits ($3.97 vs. $4.49). However, aTIV was associated with significantly lower mean annualized costs for influenza-related physician office visits ($1.10 vs. $1.36).
The study was sponsored by Seqirus Vaccines.
Postma M, Pelton S, Divino V, Mould-Quevedo J, DeKoven M, Krishnarajah G. Economic Assessment of Adjuvanted Trivalent Influenza Vaccine Compared to Trivalent High-Dose Influenza Vaccine Among the U.S. Elderly: A Comprehensive Real-World Evidence Evaluation of Direct Healthcare Costs for the 2017-2018 Influenza Season. Abstract J2. Presented during AMCP eLearning Days, April 20-24.